303 related articles for article (PubMed ID: 24000048)
1. Use of nicotinamide to treat hyperphosphatemia in dialysis patients.
Lenglet A; Liabeuf S; Guffroy P; Fournier A; Brazier M; Massy ZA
Drugs R D; 2013 Sep; 13(3):165-73. PubMed ID: 24000048
[TBL] [Abstract][Full Text] [Related]
2. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
Molony DA; Stephens BW
Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
[TBL] [Abstract][Full Text] [Related]
3. Niacin and related compounds for treating hyperphosphatemia in dialysis patients.
Berns JS
Semin Dial; 2008; 21(3):203-5. PubMed ID: 18363600
[TBL] [Abstract][Full Text] [Related]
4. Use of phosphate binders in chronic kidney disease.
Ketteler M; Biggar PH
Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
[TBL] [Abstract][Full Text] [Related]
5. Nicotinamide and phosphate homeostasis in chronic kidney disease.
Ginsberg C; Ix JH
Curr Opin Nephrol Hypertens; 2016 Jul; 25(4):285-91. PubMed ID: 27219041
[TBL] [Abstract][Full Text] [Related]
6. Phosphate balance in ESRD: diet, dialysis and binders against the low evident masked pool.
Galassi A; Cupisti A; Santoro A; Cozzolino M
J Nephrol; 2015 Aug; 28(4):415-29. PubMed ID: 25245472
[TBL] [Abstract][Full Text] [Related]
7. Targeting Gastrointestinal Transport Proteins to Control Hyperphosphatemia in Chronic Kidney Disease.
Fouque D; Vervloet M; Ketteler M
Drugs; 2018 Aug; 78(12):1171-1186. PubMed ID: 30022383
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis.
El Borolossy R; El Wakeel LM; El Hakim I; Sabri N
Pediatr Nephrol; 2016 Feb; 31(2):289-96. PubMed ID: 26420678
[TBL] [Abstract][Full Text] [Related]
9. Nicotinic acid and nicotinamide: a review of their use for hyperphosphatemia in dialysis patients.
Rennick A; Kalakeche R; Seel L; Shepler B
Pharmacotherapy; 2013 Jun; 33(6):683-90. PubMed ID: 23526664
[TBL] [Abstract][Full Text] [Related]
10. Niacin and Chronic Kidney Disease.
Taketani Y; Masuda M; Yamanaka-Okumura H; Tatsumi S; Segawa H; Miyamoto K; Takeda E; Yamamoto H
J Nutr Sci Vitaminol (Tokyo); 2015; 61 Suppl():S173-5. PubMed ID: 26598845
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy evaluation of lanthanum carbonate for hyperphosphatemia in end-stage renal disease patients.
Shigematsu T; Ohya M; Negi S; Masumoto AR; Nakashima YM; Iwatani Y; Moribata MK; Yamanaka S; Tatsuta K; Mima T
Contrib Nephrol; 2015; 185():42-55. PubMed ID: 26023014
[TBL] [Abstract][Full Text] [Related]
12. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
13. An expert update on novel therapeutic targets for hyperphosphatemia in chronic kidney disease: preclinical and clinical innovations.
Cozzolino M; Ketteler M; Wagner CA
Expert Opin Ther Targets; 2020 May; 24(5):477-488. PubMed ID: 32191548
[No Abstract] [Full Text] [Related]
14. A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients.
Cheng SC; Young DO; Huang Y; Delmez JA; Coyne DW
Clin J Am Soc Nephrol; 2008 Jul; 3(4):1131-8. PubMed ID: 18385391
[TBL] [Abstract][Full Text] [Related]
15. Hyperphosphatemia in end-stage renal disease.
Indridason OS; Quarles LD
Adv Ren Replace Ther; 2002 Jul; 9(3):184-92. PubMed ID: 12203200
[TBL] [Abstract][Full Text] [Related]
16. An update on tenapanor to treat hyperphosphatemia.
Cianciolo G; Barbuto S; Iacovella F; La Manna G; Galassi A; Ciceri P; Cozzolino M
Drugs Today (Barc); 2022 Jan; 58(1):33-53. PubMed ID: 35107092
[TBL] [Abstract][Full Text] [Related]
17. Hyperphosphatemia in Dialysis Patients: Beyond Nonadherence to Diet and Binders.
Sherman RA
Am J Kidney Dis; 2016 Feb; 67(2):182-6. PubMed ID: 26508681
[TBL] [Abstract][Full Text] [Related]
18. Control of hyperphosphatemia among patients with ESRD.
Coladonato JA
J Am Soc Nephrol; 2005 Nov; 16 Suppl 2():S107-14. PubMed ID: 16251245
[TBL] [Abstract][Full Text] [Related]
19. Hyperphosphatemia and phosphate binders: effectiveness and safety.
Kalaitzidis RG; Elisaf MS
Curr Med Res Opin; 2014 Jan; 30(1):109-12. PubMed ID: 24007207
[TBL] [Abstract][Full Text] [Related]
20. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
